Recomienda este artículo a tus amigos:
Resistance to Targeted Therapies in Breast Cancer 1st ed. 2017 edition
Resistance to Targeted Therapies in Breast Cancer
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling).
184 pages, 12 Illustrations, black and white; XV, 184 p. 12 illus.
| Medios de comunicación | Libros Book |
| Publicado | 13 de diciembre de 2017 |
| ISBN13 | 9783319701417 |
| Editores | Springer International Publishing AG |
| Páginas | 184 |
| Dimensiones | 150 × 220 × 20 mm · 462 g |
| Lengua | Alemán |
| Editor | Prosperi, Jenifer R. |